profitfromit1@gmail.com

Apollo Hospitals Q3 FY26 Analysis:

Lesson 231/323 | Study Time: 10 Min

Course: Quarterly Result Updates & Analysis

Apollo Hospitals Q3 FY26 Analysis: Aggressive Bed Expansion vs. Digital Path to Profitability

The healthcare landscape in India is shifting toward high-volume, high-acuity care. In Q3 FY26, Apollo Hospitals demonstrated its market leadership by balancing a massive 3,500-bed expansion plan with the ongoing turnaround of its digital and pharmacy arm, HealthCo.

1. The Snapshot

Attribute	Details
Company Name	Apollo Hospitals Enterprise Ltd (AHEL)
Current Market Price (CMP)	₹7,537.45
Market Capitalization	~₹1,08,370 Cr
Sector	Healthcare Services & Pharmacies
Quick Verdict	Strategic Accumulate - Steady core growth with a digital "S-curve" inflection point nearing.

2. The 'Wow' Factor

Massive Bed Pipeline: Management confirmed a rollout of 3,500 new beds over the next 4 financial years, with 750 beds coming online in the next 12 months.
HealthCo Break-even: Apollo HealthCo (Pharmacy + Digital) reported a significant reduction in losses, moving closer to the guided cash break-even by Q4 FY26.
Acuity Premium: Revenue from high-end surgical procedures (Cardiac, Oncology, Neuro) saw a 14% YoY increase, contributing to superior ARPOB.
Strategic Acquisition: Completed the acquisition of Belenus Champion Hospitals in Bengaluru to strengthen its presence in the high-growth Karnataka cluster.

3. Operational KPI Table (Hospitals & HealthCo)

We track these metrics as the primary drivers of value in a hospital-cum-retail pharmacy model.

KPI	Q3 FY26	Q3 FY25	YoY Change
ARPOB (₹ Per Day)	₹62,450	₹57,800	+8.0%
Occupancy Rate (%)	68%	66%	+200 bps
Apollo 24/7 GMV	₹940 Cr	₹710 Cr	+32.4%
In-patient Volumes	1,52,400	1,44,000	+5.8%

4. Financial Deep Dive (Consolidated)

The core hospital business continues to subsidize the high-growth digital segment.

Metric (₹ Cr)	Q3 FY26	Q3 FY25	YoY Growth	QoQ Growth
Revenue	5,586	4,851	15.1%	2.4%
EBITDA	762	640	19.1%	3.1%
PAT	315	245	28.6%	5.2%

Cost vs. Efficiency Analysis

Total operating expenses rose by 13.5%, primarily driven by higher clinical talent costs and marketing for the 24/7 platform. However, the EBITDA margin expanded to 13.6% (up from 13.2% YoY). We note that the "Efficiency Ratio" calculated as:

$$\text{Efficiency Ratio} = \frac{\text{Direct Costs}}{\text{Operating Revenue}} \times 100$$

improved by 85 bps, indicating that the premiumization of services (higher ARPOB) is successfully offsetting medical inflation.

5. Peer Benchmarking: Apollo vs. Fortis

Apollo continues to trade at a premium to Fortis Healthcare due to its integrated pharmacy ecosystem. While Fortis has shown slightly better occupancy recovery, Apollo’s ARPOB of ₹62,450 remains ~15% higher than Fortis’s estimated average, reflecting Apollo’s superior Case Mix Index (CMI).

6. The Forward Curve

Management guidance suggests a strong pipeline. We project:

Q4 FY26: Expect seasonal strength in elective surgeries; Revenue target of ₹5,850 Cr.
Q1 FY27: Likely impact from the commissioning of the new Pune and Gurgaon facilities; short-term margin pressure due to "pre-operating" costs.

7. Valuation Guardrails

Apollo is currently trading at a TTM P/E of ~82x, which is slightly above its 5-year median of 74x.

Verdict: Trading at a Premium.
Justification: The market is pricing in the eventual profitability of the 24/7 platform and the value unlock from the recent stake sale in HealthCo to Advent International.

8. Shareholding Pattern Shifts

Recent filings indicate a stable promoter stake at 29.3%. However, FII (Foreign Institutional Investors) holding increased by 42 bps this quarter, signaling global confidence in India's medical tourism story.

9. The Advisory Note

Strategic vs. Tactical:

Strategic (Long-term): Apollo is no longer just a "sick-care" hospital; it is becoming a "health-tech" aggregator. The long-term thesis remains intact as long as HealthCo reaches net profitability by FY27.
Tactical (Price Opportunity): At ₹7,500+, the stock is not "cheap." A margin of safety exists only if the new 3,500 beds reach 40% occupancy within the first year of operations. Investors should look for entries during market corrections.

Management Integrity: The tone was Transparent and Confident. Management did not shy away from discussing the high debt associated with expansion, providing a clear repayment roadmap through internal accruals.

Fairvalue:

https://docs.google.com/spreadsheets/d/e/2PACX-1vQOMnZIv8DDDbZLRh0SD6MbjtDp7du4Vs3iwpLUQf0fFzltPpWPmA3dv8PjGCsv3A/pubhtml?gid=81663420&single=true

Mandatory Disclosure: This report is for educational and informational purposes only and does not constitute financial advice. Equity investments are subject to market risks..

Previous Lesson Next Lesson

Piyush Patel

Product Designer

4.83

Profile

Class Sessions